Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction accompanied by chronic inflammation. It is one of the leading causes of morbidity and mortality worldwide and is often caused by environmental exposure such as cigarette smoke \[[@CR1]\]. COPD exacerbations, periods of acute deterioration, are a major reason for COPD mortality and a major source of the high healthcare expenditure in patients with COPD. Acute exacerbations of COPD are characterized by symptoms of shortness of breath, cough, and sputum production. Although these exacerbations are often caused by bacterial or viral infections \[[@CR2]\] or inhaled particles, the variability in occurrence within COPD patients and the familial aggregation of exacerbations indicate that other factors such as genetics are important in determining the onset, severity and frequency \[[@CR3]\]. Also, the frequency of acute exacerbations appears to be a stable trait \[[@CR4]\], supporting genetic susceptibility, and loci associated with COPD exacerbations have been identified \[[@CR5],[@CR6]\].

Despite the fact that gene expression data from lung tissues should provide greater sensitivity to detect the molecular signature of COPD exacerbations, COPD is a systemic disease, and blood is more accessible for genomics and biomarkers studies in large scale clinical trials and potentially in clinical practice than is lung tissue samples. Previous attempts to study lung disease via whole blood experiments have been successful while studying asthma \[[@CR7]\] and idiopathic pulmonary fibrosis \[[@CR8],[@CR9]\]. Further supporting the use of blood expression profiling, previous COPD studies have documented differential expression in overlapping genes from both blood and lung samples \[[@CR10],[@CR11]\]. Gene expression in peripheral blood has been associated with COPD and related phenotypes \[[@CR12]\].

Network medicine approaches provide a roadmap towards the understanding of complex diseases by studying interacting gene sets and pathways, instead of individual genetic determinants \[[@CR13],[@CR14]\]. Network medicine techniques have been applied to the study of COPD \[[@CR15]\].

We hypothesized that we could identify a signature of frequent COPD exacerbations using gene expression data and protein biomarker data, both collected from peripheral blood samples. The goal is to use network methods to understand the molecular pathogenesis of COPD exacerbations, and perhaps predict onset through minimally invasive means. This study built upon the prior publications involving the use of peripheral blood to examine the molecular pathogenesis of COPD and other complex diseases \[[@CR8],[@CR11],[@CR12]\], and leveraged the power of network analysis methods to uncover gene expression signatures.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This analysis used expression data from 248 Caucasian COPD subjects from the Treatment of Emphysema with a Selective Retinoid Agonist (TESRA), a randomized controlled trial of palovarotene for treatment of COPD (clinicaltrials.gov identifier NCT00413205) \[[@CR16],[@CR17]\]. TESRA subjects were former smokers with COPD who experienced two or fewer exacerbations requiring outpatient treatment with antibiotics or oral steroids or one exacerbation requiring hospitalization within the prior year. The total number of subjects in the study was 410. In our analysis, the number of exacerbations in the year prior to enrollment was considered both as a linear variable (0,1,2) and as a binary variable (0 vs. 1 or more). The baseline blood samples, from which our analysis data were obtained, were collected prior to randomization and any treatment associated with the clinical trial. Quantitative emphysema measurements were performed on chest computed tomography (CT) scans, including percent of lung with attenuation (%LAA) ≤ −910 HU and mean lung attenuation at the 15th percentile on lung attenuation curve (Perc15). The baseline phenotype data in our analyses were obtained prior to randomization and any treatment. All subjects provided written informed consent. TESRA was approved by the Institutional Review Boards at all participating centers (see Additional file [1](#MOESM1){ref-type="media"}).

Gene expression data {#Sec4}
--------------------

RNA was isolated from whole blood samples collected in PaxGene RNA tubes (PreAnalytiX, Franklin Lakes, NJ). Gene expression data were obtained using the Affymetrix Human Genome U133 Plus 2.0 Array. Data were available for 309 samples, including 39 replicates, as outlined in Additional file [2](#MOESM2){ref-type="media"}: Table S1. Of the 270 remaining unique arrays, three were found to be outliers during the quality control process and were discarded. All 54,675 probes passing quality control were retained regardless of level of variance across samples. These data were background corrected and quantile normalized using the robust multi-array average (RMA) method via the R Bioconductor package affy \[[@CR18]\]. The 249 subjects that self-identified as Caucasian were included. Using information from a GWAS, one additional subject was omitted based on a genetic ancestry that did not cluster with the other Caucasian subjects, leaving 248 subjects for analysis.

Protein biomarkers {#Sec5}
------------------

A total of 140 plasma biomarkers were measured in duplicate at Rules Based Medicine (Austin, TX) and Quest Diagnostics (Valencia, CA), as previous described \[[@CR17]\]. Biomarker data are available for 245 of the 248 subjects with associated gene expression data. Any biomarker with greater than 10% and less than 95% of its values below the lower limit of quantitation (LLOQ) were converted to a binary present vs. absent variable (n = 25). Two biomarkers with greater than 95% values below the LLOQ were excluded from the analysis. An empirical normal quantile transformation was performed on the 113 remaining continuous biomarker values. Model \#1 from Additional file [2](#MOESM2){ref-type="media"}: Table S2 was used to assess the association of biomarker levels with the number of recent exacerbations. Logistic regression was used for the binary biomarker values, and linear regression was used for the continuous biomarker values.

Gene expression analysis {#Sec6}
------------------------

Microarray batch effects visible from MDS plots were addressed by adjusting for the microarray lot number as a covariate. For each expression probe, biomarker or module eigengene, we fitted a linear regression model to detect association with variables of interest using R statistical software (v 3.0.2). In the microarray data analysis, an empirical Bayes shrinkage method was used to obtain a moderated t-test statistic and its p-value in the R Bioconductor package limma \[[@CR19]\]. Adjustment for multiple testing controlled for false discovery rate (FDR) \[[@CR20]\]. The regression models for each COPD phenotype are provided in Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Weighted Gene Co-expression Analysis (WGCNA) {#Sec7}
--------------------------------------------

The WGCNA method was used to identify groups of probes that have similar expression in the sample population, using the R package WGCNA \[[@CR21]\]. In order to identify possible sample outliers, a sample network based on squared Euclidean distances was built. An iterative approach was taken, where samples having a standardized connectivity below −5 were removed \[[@CR21]\]. One sample outlier was excluded using this process, leaving 247 subjects. Signed networks were built using biweight midcorrelation as the correlation function, and a soft thresholding power of 12. WGCNA produces a set of modules (labeled by color), each containing a set of unique genes. The module eigengene is defined as the first principal component of the expression matrix of the probes within the module. For association tests, the module eigengenes are included in the regression models from Additional file [2](#MOESM2){ref-type="media"}: Table S2, similar to the expression probes, and adjustment for multiple testing was performed using Bonferroni correction, where the burden is reduced in comparison with a probe-based analysis. Driver or hub genes within each module are the probes with both high gene significance (GS) and high module membership (MM) metrics, represented by the p-value for the test of gene expression association with phenotype, and the correlation of gene expression with the module eigengene, respectively.

Pathway analysis {#Sec8}
----------------

We examined enrichment of curated gene sets from the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases in the gene groups from association tests or the co-expression modules using a hypergeometric test in the R Bioconductor package GeneAnswers \[[@CR22]\]. In the GO analysis, only the biological process (BP) category was considered. Further examination of the gene sets was performed using the gene set enrichment analysis (GSEA) to examine up- and down-regulated genes common to previous experiments and curated gene sets within all available MSigDB collections \[[@CR23]\]. The query gene lists (top association test results or module genes) were preranked according to their log fold change values from the gene expression association tests. GSEA was performed on both a set of all probes and subsets of probes from WGCNA modules, using a similar concept to the GO and KEGG analyses. The Cytoscape plug-in EnrichmentMap \[[@CR24]\] was used to plot the relationships between the individual GSEA results, as well as between the sets of results from different analyses.

Results {#Sec9}
=======

Gene expression association with phenotype variables {#Sec10}
----------------------------------------------------

Characteristics of study subjects are shown in Table [1](#Tab1){ref-type="table"}. The top five expression probesets ranked by p-value for association with number of exacerbations in the past 12 months are provided in Additional file [2](#MOESM2){ref-type="media"}: Table S3. After controlling for FDR, no probes were statistically significant. The results for all other models are also provided in Additional file [2](#MOESM2){ref-type="media"}: Table S3, where only one probe across the COPD-related phenotypes was found to be significant at FDR \< 0.05, for the six minute walk test. This probe did not have a gene annotation and maps to a region with no obvious biological significance. Enrichment tests were performed using the set of genes within the regression results having a p \< 0.05 for the exacerbation phenotype (Table [2](#Tab2){ref-type="table"}). Although the KEGG results demonstrate an enrichment of autoimmune-related genes, the overall results indicate a lack of specificity, as demonstrated by the presumably-unrelated diseases represented. In addition, the GO results are very broad, with processes related to protein ubiquitination and regulation of calcium concentration being dominant. To improve specificity, we used a network approach, whereby genes with similar characteristics may be grouped prior to pathway analysis.Table 1**TESRA study subjectsDemographicsn = 248 expression (n = 245/248 biomarker)Association with exacerbations**Age (years)66.4 +/− 7.9linear regression p-value = 0.11GenderFemale 78Fisher\'s Exact Test p-value = 0.86Male 170RaceCaucasian 100%NAFormer smokers100%NASmoking history (pack-years)47 +/− 24.3linear regression p-value = 0.02BMI26 +/− 4.7linear regression p-value = 0.39**COPD outcomes**Exacerbations in past 12 months0 n = 1231 n = 1022 n = 23FEV1 (L)1.34 +/− 0.35FEV1 % predicted48.8 +/− 9.3FEV1/FVC0.43 +/− 0.09% LAA ≤ −910 HU41.65 +/− 16.2Perc15 (HU)−946 +/− 23.6TLC (L)6.9 +/− 1.4TLC % predicted101.6 +/− 15.4DLCO (mL/min/mmHg)12.3 +/− 3.96 minute walk test (m)317.5 +/− 111.2Residual volume % predicted120.1 +/− 31Inspiratory capacity (L)2.4 +/− 0.67Table 2**Top categories enriched in association results for exacerbation phenotype (gene n = 999)GO categoryIDGenes in categoryp-valueFDR q-value**Protein ubiquitinationGO:0016567232.78E-0084.42E-006Purine ribonucleoside triphosphate catabolic processGO:0009207172.40E-0064.78E-005Guanosine-containing compound catabolic processGO:1901069161.04E-0062.69E-005Calcium ion homeostasisGO:0055074153.16E-0071.68E-005Epidermal growth factor receptor signaling pathwayGO:0007173141.18E-0079.37E-006Cellular calcium ion homeostasisGO:0006874141.12E-0062.69E-005Activation of protein kinase activityGO:0032147102.68E-0042.66E-003Negative regulation of protein serine/threonine kinase activityGO:007190199.97E-0072.69E-005**KEGG categoryIDGenes in categoryp-valueFDR q-value**Cell adhesion molecules (CAMs)04514133.86E-0031.44E-001B cell receptor signaling pathway04662112.72E-0044.75E-002T cell receptor signaling pathway04660115.62E-0031.54E-001Antigen processing and presentation04612101.23E-0035.73E-002Chagas disease (American trypanosomiasis)05142101.20E-0022.23E-001Primary immunodeficiency0534075.37E-0044.75E-002Allograft rejection0533077.66E-0044.75E-002Autoimmune thyroid disease0532075.81E-0031.54E-001

Network analysis {#Sec11}
----------------

A weighted gene co-expression network was constructed as outlined in Methods. The final network consisted of 32 modules, ranging in size from 30 to 19,748 probes. Two dendrograms of the module structure are presented in Additional file [2](#MOESM2){ref-type="media"}: Figures S1-S2, as the number of probes (54,675) dictated that the network be built in two blocks. There was high correlation within the modules as expected, with the mean module membership (MM), or mean correlation of gene expression with the module eigengene, varying from 0.54 to 0.81 across all modules of interest. The grey module is a grouping of probes with outlying gene expression profiles and was not considered further.

Tests of association between COPD phenotypes and the module eigengenes were performed for each model in Additional file [2](#MOESM2){ref-type="media"}: Table S2, and summarized in Figure [1](#Fig1){ref-type="fig"}. Across all phenotype variables and modules, only the white module (number of probes, n = 57) was significant after controlling for FDR (q-value = 0.02) for the association with the number of exacerbations within the year prior to enrollment. In addition, four other modules were nominally significant (p \< 0.05) for the association with exacerbations (royalblue n = 118, lightgreen n = 147, darkturquoise n = 73, darkgrey n = 65) (Additional file [2](#MOESM2){ref-type="media"}: Table S4). All probesets in these modules had variance above the lower 5%ile for all probesets. The top modules associated with both exacerbations phenotypes were similar (Additional file [2](#MOESM2){ref-type="media"}: Table S5).Figure 1**Heatmap of module association with phenotype variables (color scale for adjusted p-value).** The top number in each cell corresponds to the FDR q-value and the bottom number is the effect from the linear regression. Variable definitions are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Lacking similar support across the results for the other phenotypes, we chose to focus exclusively on the exacerbations phenotype for the remainder of the study. The putative hub genes for the five modules of interest are highlighted in the lists of module genes in Additional file [2](#MOESM2){ref-type="media"}: Tables S6-S10. These hub genes with low gene significance (GS) p-values and high module membership (MM) correlations for the five modules include IGHM (immunoglobulin heavy constant mu; GS =0.002, MM = 0.9), KLRD1 (killer cell lectin-like receptor subfamily D, member 1; GS = 0.006, MM = 0.89 and GS = 0.007, MM = 0.88), AFF3 (AF4/FMR2 family, member 3; GS = 0.0014, MM = 0.8), GPR56 (G protein-coupled receptor 56; GS = 0.00024, MM = 0.8), and GBP5 (guanylate binding protein 5; GS = 0.009, MM = 0.77 and GS = 0.016, MM = 0.77) and GBP1 (guanylate binding protein 1, interferon-inducible; GS = 0.028, MM = 0.87).

GO and KEGG pathway analyses were performed on the five modules above. The results are provided in Table [3](#Tab3){ref-type="table"} for the white module and Additional file [2](#MOESM2){ref-type="media"}: Tables S11-S14 for the other four modules. In contrast to the results for the overall gene expression association, the enrichment tests for each module provide more specific functional signatures, with B cell receptor signaling and autoimmune disease being enriched in the results for the white module; B cell pathway is also seen in the lightgreen module results. The darkgrey and darkturquoise module results are highlighted by cytokine activity, with the darkgrey module showing a strong signal for interferon activity and viral response pathways.Table 3**Top eight pathway analysis results for white module (unique gene symbols n = 32)GO categoryIDGenes in categoryp-valueFDR q-value**B cell receptor signaling pathwayGO:005085320.000720.10Antigen processing and presentation of exogenous peptide antigen via MHC class IIGO:001988620.00550.13Antigen receptor-mediated signaling pathwayGO:005085120.0110.13Skeletal muscle tissue developmentGO:000751920.0290.18Skeletal muscle organ developmentGO:006053820.0310.18Clustering of voltage-gated potassium channelsGO:004516310.00360.13Protein localization to juxtaparanode region of axonGO:007120510.00480.13Positive regulation of humoral immune response mediated by circulating immunoglobulinGO:000292510.00730.13**KEGG categoryIDGenes in categoryp-valueFDR q-value**B cell receptor signaling pathway0466247.6E-0060.00018Cell adhesion molecules (CAMs)0451447.4E-0050.00088Asthma0531021.4E-0030.011Allograft rejection0533022.1E-0030.011Graft-versus-host disease0533222.5E-0030.011Type I diabetes mellitus0494022.8E-0030.011Intestinal immune network for IgA production0467223.4E-0030.012Autoimmune thyroid disease0532024.0E-0030.012

GSEA was performed on the five modules, and the results meeting the FDR q-value \< 0.25 are provided in Table [4](#Tab4){ref-type="table"}. B cell, T-cell and viral response signatures dominate the results, with the white, royalblue and darkgrey modules demonstrating enrichments for viral response gene sets. EnrichmentMap networks were constructed for the darkgrey and lightgreen modules, two longest lists from Table [4](#Tab4){ref-type="table"}. These are shown in Figure [2](#Fig2){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}: Figure S3, respectively. The darkgrey module network shows multiple highly-connected nodes related to viral response. An EnrichmentMap network was also produced using the GSEA results for the set of genes nominally associated (p \< 0.05) with the exacerbations phenotype (model \#1); the GSEA results are provided in Additional file [2](#MOESM2){ref-type="media"}: Table S15 and the EnrichmentMap network is shown in Additional file [3](#MOESM3){ref-type="media"}: Figure S4. Many similar immune cell gene sets are seen, along with multiple non-specific results such as cancer gene sets.Table 4**GSEA results for modules associated with exacerbations phenotypes (gene sets with FDR q-value \< 0.25 are shown and viral response gene sets are in bold)Module nameGene set descriptionIDSet overlapP-valueFDR q-value**White (negative)\*NAIVE_BCELL_VS_MONOCYTE_UPGSE22886150.0840.207CD4_TCELL_VS_BCELL_DNGSE10325180.1220.230**BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_PGSE29618**170.1850.216Royalblue (positive)\*NAIVE_VS_PD1LOW_CD8_TCELL_DNGSE26495280.0040.048**HEALTHY_VS_RSV_INF_INFANT_PBMC_UPGSE34205**150.0160.062DEURIG_T\_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN180.0550.151Lightgreen (negative)\*BCELL_VS_MDC_DAY7_FLU_VACCINE_UPGSE29618170.0060.095CD4_TCELL_VS_BCELL_DNGSE10325190.0120.05BCELL_VS_MDC_UPGSE29618150.0120.043LUPUS_CD4_TCELL_VS_LUPUS_BCELL_DNGSE10325200.010.046DODD_NASOPHARYNGEAL_CARCINOMA_UP150.0230.068BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_UPGSE29618210.0250.064BCELL_VS_MYELOID_UPGSE10325150.0450.064NAIVE_BCELL_VS_MONOCYTE_UPGSE22886170.060.078BCELL_VS_MONOCYTE_UPGSE29618230.0750.121CAGGTG_V\$E12_Q6160.1160.149MEMORY_CD4_TCELL_VS_BCELL_DNGSE3982170.1370.14Darkturquoise (positive)\*NAIVE_VS_PD1LOW_CD8_TCELL_DNGSE26495260.0570.090NAIVE_VS_PD1HIGH_CD8_TCELL_DNGSE26495190.1580.166Darkgrey (positive)\*CTRL_VS_NEWCASTLE_VIRUS_DC_8H_DNGSE18791300.0000.012**BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE**18**0.0030.038**UNSTIM_VS_4H_LPS_DC_TRANSLATED_RNA_DNGSE14000230.0020.030MOSERLE_IFNA_RESPONSE170.0110.104TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP200.0160.094UNSTIM_VS_NEWCATSLE_VIRUS_DC_18H_DNGSE18791190.0130.093UNSTIM_VS_NEWCATSLE_VIRUS_DC_6H_DNGSE18791310.0310.105CTRL_VS_NEWCASTLE_VIRUS_DC_10H_DNGSE18791210.0130.095CTRL_VS_NEWCASTLE_VIRUS_DC_12H_DNGSE18791190.0260.134UNSTIM_VS_4H_LPS_DC_DNGSE14000240.0310.141UNSTIM_VS_NEWCATSLE_VIRUS_DC_10H_DNGSE18791260.0340.161CTRL_VS_NEWCASTLE_VIRUS_DC_4H_DNGSE18791220.0520.166CTRL_VS_NEWCASTLE_VIRUS_DC_6H_DNGSE18791270.0540.170BCELL_VS_LUPUS_BCELL_DNGSE10325170.0940.250HECKER_IFNB1_TARGETS210.1020.246\*Positive or negative correlation between module and phenotype.Figure 2**EnrichmentMap network for GSEA results from darkgrey module.** Nodes correspond to gene sets and edges correspond to an overlap of the genes within two sets.

Biomarker association with exacerbations phenotype {#Sec12}
--------------------------------------------------

The association between the number of exacerbations and each of the plasma biomarkers was tested adjusting for covariates and the top ten results are provided in Table [5](#Tab5){ref-type="table"}. Myeloperoxidase (MPO) was the top result (FDR q-value = 0.096), while club cell-16 (CC-16) showed nominal association (p \< 0.05).Table 5**Biomarker association with exacerbation phenotypeBiomarkerBetaStandard errorP-ValueFDR q-value**MPO0.330.0960.000690.096CC_160.200.0980.0410.98ET1_Z−0.440.250.0740.98HPT0.160.0940.0860.98ENA780.180.110.0940.98TNFB−0.320.200.110.98TP−0.160.100.120.98TSH0.150.100.130.98APOH−0.150.100.140.98TGFB30.300.200.140.98

Discussion {#Sec13}
==========

In order to identify genes associated with COPD-related phenotypes, we initially used standard gene expression models. Despite the sample size, we found a lack of significant results, and a lack of specificity with respect to pathways or diseases from the enrichment analyses. However, network methods were able to group similar probes into correlated modules with potential common functions, that were then tested for association with phenotypes of interest. Using these methods we were able to observe immunological functions across the modules associated with acute exacerbations of COPD. In addition, we were able to recapitulate the molecular signatures of previous studies involving viral lung infections and exacerbations of asthma, a related respiratory disease. The ability to uncover such signatures is limited given that only subjects having two or fewer exacerbations within the previous year were included in the study, as a wider range of exacerbation frequencies would provide greater resolution to detect the molecular underpinnings of COPD exacerbations. Yet the network methods added value to address these limitations of the dataset.

WGCNA allowed for identification of the putative hub genes for each of the five modules associated with exacerbations. These hubs include the immunoglobulin heavy constant mu (IGHM) gene in the white module, that codes for the C region of the mu heavy chain (defines the IgM isotype). Lending to its role in lung disease, IGHM was found to be down-regulated in idiopathic pulmonary fibrosis (IPF) whole blood samples versus normal samples \[[@CR9]\]. From the royalblue module, the putative hub was found to be KLRD1 (CD94) that codes for an antigen preferentially expressed on NK cells. A decrease in its expression has been observed in the blood of COPD patients versus controls \[[@CR25]\]. The gene product for AFF3 from the lightgreen module is a tissue restricted nuclear transcriptional activator, formerly known as lymphoid nuclear protein related to AF4, and it was down-regulated with respect to controls in BEAS-2B cells (immortalized human bronchial epithelial cells) treated with low doses of cigarette smoke condensate \[[@CR26]\]. From the darkturquoise module, GPR56 encodes G protein-coupled receptor 56; its involvement in COPD has not been previously established. Lastly, the hubs from the darkgrey module, GBP1 and GBP5, guanylate binding proteins whose expression is induced by interferon and are markers of M1 macrophage population, were found to be down-regulated by cigarette smoke in monocyte-derived macrophages \[[@CR27]\]. Taken as a whole, these hubs lend additional evidence to the specific role of each module: B cell activity for the white and lightgreen modules, NK cell activity for the royalblue module, and macrophage involvement in the darkgrey module.

GO and KEGG pathway enrichment analysis provided common functions of the module genes, namely the immune system response to bacterial and viral infections. Additionally, the significant enrichment for B cell and asthma pathways in the white module are of note, as are the cytokine and viral response related enrichments in the darkturquoise and darkgrey modules. However, the GSEA results were more informative, revealing signatures of gene expression previously identified in studies involving lung infections, which is consistent with the infectious etiology of most COPD exacerbations. One example was a top result for the darkgrey module (Table [4](#Tab4){ref-type="table"}). The gene set, BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE, was a WGCNA module (n = 78 genes) composed of genes downstream of interferon signaling, that was associated with lung function in a study of sputum samples of children with acute asthma exacerbations \[[@CR28]\]. This study found decreased activation of interferon pathways in asthmatic children with chronic airway obstruction compared with those without airway obstruction. The darkgrey module may harbor genes associated with differential responses during exacerbations that perhaps also play a role in onset, frequency and severity of COPD exacerbations.

In another example, the royalblue module enrichment results include the gene set GSE34205_HEALTHY_VS_RSV_INF_INFANT_PBMC_UP, genes differentially expressed in blood samples from healthy infants and infants suffering from respiratory syncytial virus (RSV) infection \[[@CR29]\]. RSV is a major respiratory pathogen that is more common in infants; however the elderly and patients with COPD or other lung diseases are also at risk of developing RSV infections \[[@CR2]\]. Using network analysis methods and GSEA, we were able to identify modules that contain genes demonstrating a signature previously seen in the sputum of patients suffering from acute asthma exacerbations and the blood of patients with respiratory infections. However, we detected these signatures using expression data from whole blood of COPD patients, collected months following exacerbations.

The EnrichmentMap network of GSEA results for the darkgrey module (Figure [2](#Fig2){ref-type="fig"}) shows an overlap between the asthma exacerbation \[[@CR28]\] and the viral-response gene sets, as would be expected given the virus-induced nature of many exacerbations. However the relatively narrow widths of many edges demonstrate that these gene sets are largely distinct. In the network for the lightgreen module in Additional file [2](#MOESM2){ref-type="media"}: Figure S3, relatively strong connections exist between the nodes, demonstrating an enrichment of B cell pathway activity within the gene sets. In contrast to the specificity of the networks for the darkgrey and lightgreen modules, the EnrichmentMap for the probe-based analysis gene set shown in Additional file [2](#MOESM2){ref-type="media"}: Figure S4 is less tightly connected with many nodes having zero connections. The probe-based analysis is less specific than the module analyses. Although the red sub-network in Additional file [2](#MOESM2){ref-type="media"}: Figure S4 contains several viral response results, the blue sub-network contains various cancer gene sets, in addition to infectious diseases.

In the biomarker analysis, we found an association between MPO and the number of exacerbations, persisting months following illness. Serum MPO levels have been shown to be increased in COPD patients during acute exacerbations \[[@CR30]\]. However in contrast to our finding, a previous study did not find a difference in sputum MPO levels between patients with stable COPD having frequent (\>3/year) or infrequent (\<2/year) exacerbations in the previous 12 months \[[@CR31]\]. In addition, a study of bronchoalveolar lavage samples did not find significantly higher MPO levels in COPD patients with frequent (≥3/year) exacerbations as compared to infrequent (\<3/year) exacerbations \[[@CR32]\]. Perhaps the peripheral blood based signature of COPD exacerbations is able to persist due to systemic modulation of the immune system. Longitudinal studies have shown a reduction in serum MPO levels during treatment for acute exacerbations of chronic bronchitis, followed by the return to higher levels following treatment \[[@CR33]\], however no association with the number of exacerbations or their severity was noted. Taken together, our finding and the previous studies provide evidence for MPO as part of the molecular signature to be considered when predicting the onset, severity and frequency of future COPD exacerbations, as it has been previously established as an inflammatory marker, and specifically in COPD \[[@CR34]\].

The use of gene expression data from whole blood instead of lung tissue samples may limit the ability of our approach to detect signatures in the specific disease tissue. However, peripheral blood is more easily accessed than lung tissue and may provide specific insight into the infectious, immune and inflammatory mechanisms of COPD exacerbations. Like lung tissue, whole blood is a complex mixture of different cell types. Complete blood counts (CBC) with cell differentials are routinely measured in clinical practice, but were not available in the TESRA study. However, our analysis was able to distinguish B and T cell signatures, cell types which would not be discriminated in a standard CBC. An additional limitation of our approach involves the use biomarker and gene expression data as markers of exacerbations in the past year, yet this may indicate a stable molecular signature differing from that of lung function and other markers of severity. Lastly, one potential confounder is the external trigger of the exacerbation. Regardless of an individual's genetic predisposition for exacerbations, a viral, bacterial or other environmental cause may lead to different signatures. Despite these limitations, we were able to effectively uncover expression signatures of frequent COPD exacerbations in peripheral whole blood samples.

Conclusions {#Sec14}
===========

In this study a distinct signature of COPD exacerbations was observed in peripheral whole blood months following the illness. This signature was correlated with previous studies involving exacerbations in asthma and viral lung infections, and therefore, it may be useful in uncovering the molecular pathogenesis of COPD exacerbations. The moderate association of MPO and number of exacerbations adds to the body of information supporting the use of MPO as a biomarker. Future studies with longitudinal expression data would allow an investigation of the temporal nature of the network modules, separating causal modules from the downstream modules demonstrating expression changes as a result of the disease state. Similarly, the methods presented here would benefit from gene expression data obtained during acute exacerbations, in addition to samples obtained months following the illness, particularly with respect to prediction. Overall, these approaches will help to elucidate the genetic component determining the heterogeneity of onset, severity, and frequency of exacerbations seen in COPD patients.
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